World
STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
- The agreements will allow the manufacturers — three of which are based in Africa and four in India — to sell generic versions to both public and private buyers, which is designed to ensure the medicine becomes available to the widest possible population.
- Moreover, the deals are royalty free, which makes it easier for the generic companies to predict costs.
- The timing of the announcement is notable because Merck is striking these deals while its medicine, known as alimatravir, is currently undergoing a pair of late-stage clinical trials.
- By doing so now, the company believes it will help the generic makers plan for wide-scale production and the necessary steps to receive regulatory approvals around the world.
Amid rising concern over efforts to contain HIV, Merck has reached voluntary licensing deals with seven companies to make generic versions of an experimental, once-a-month prevention pill in 129 low- and middle-income countries. The agreements will allow the manufacturers — three of which are based in Africa and four in India — to sell generic versions to both public and private buyers, which is designed to ensure the medicine becomes available to the widest possible population. Moreover, the deals are royalty free, which makes it easier for the generic companies to predict costs.
The timing of the announcement is notable because Merck is striking these deals while its medicine, known as alimatravir, is currently undergoing a pair of late-stage clinical trials. By doing so now, the company believes it will help the generic makers plan for wide-scale production and the necessary steps to receive regulatory approvals around the world. Continue to STAT+ to read the full story… Amid rising concern over efforts to contain HIV, Merck has reached voluntary licensing deals with seven companies to make generic versions of an experimental, once-a-month prevention pill in 129 low- and middle-income countries.
Understand how science, health policy, and medicine shape the world every day Pharmalot Pharmalot July 23, 2026 STAT Plus: Pharmalittle: We're reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more By Ed Silverman Pharmalot Pharmalot July 23, 2026 STAT Plus: FDA is urged by advocacy group to ban DTC prescription drug ads By Ed Silverman Pharmalot Pharmalot July 22, 2026 STAT Plus: Pharmalittle: We're reading about Trump's plan for tariffs on generics, a Merck and Gilead HIV pill, and more By Ed Silverman Pharmalot Pharmalot July 21, 2026 STAT Plus: Pharmalittle: We're reading about Novo suing Lilly over 'deceptive' ads, a fugitive's secret life in biotech, and more By Ed Silverman The timing of the announcement is notable because Merck is striking these deals while its HIV pill is currently undergoing two late-stage trials.
Source: STAT News